Palazestrant Clinical Trials (2026): 5 Studies for Metastatic Breast Cancer & Breast Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 Palazestrant clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Metastatic Breast Cancer & Breast Cancer) and 1,940 total planned enrollment. 2 Phase 3 Palazestrant trials are listed. 3 Palazestrant clinical trials are actively recruiting at 54 U.S. sites across 26 states. Most recent activity: NCT07085767 (Jan 2032).
Where to Participate: All Palazestrant Trial Sites in the U.S. (54 sites across 26 states)
Every actively recruiting Palazestranttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT05508906 | Map |
| CA | Clinical Trial Site | Beverly Hills90211 | NCT07085767 | Map |
| CA | Clinical Trial Site | La Jolla92093 | NCT07085767 | Map |
| CA | Clinical Trial Site | Los Alamitos90720 | NCT07085767 | Map |
| CA | Clinical Trial Site | San Francisco94115 | NCT07085767 | Map |
| CA | University of California San Francisco Health | San Francisco94158 | NCT05508906 | Map |
| CA | Clinical Trial Site | Vallejo94589 | NCT07085767 | Map |
| CO | University of Colorado Cancer Center | Aurora80045 | NCT05508906 | Map |
| CO | Clinical Trial Site | Denver80220 | NCT07085767 | Map |
| CT | Clinical Trial Site | New Haven06511 | NCT07085767 | Map |
| FL | Advent Health Hematology and Oncology | Orlando32804 | NCT05508906 | Map |
| FL | Florida Cancer Specialists | Sarasota34232 | NCT06784193 | Map |
| FL | Clinical Trial Site | Tampa33612 | NCT07085767 | Map |
| GA | Clinical Trial Site | Marietta30060 | NCT07085767 | Map |
| HI | Clinical Trial Site | Honolulu96813 | NCT07085767 | Map |
| IL | Clinical Trial Site | Peoria61615 | NCT07085767 | Map |
| IL | Clinical Trial Site | Urbana61801 | NCT07085767 | Map |
| IA | University of Iowa | Iowa City52242 | NCT05508906 | Map |
| LA | University Medical Center - New Orleans | New Orleans70112 | NCT06784193 | Map |
| ME | Clinical Trial Site | Scarborough04074 | NCT07085767 | Map |
| MD | Clinical Trial Site | Annapolis21401 | NCT07085767 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT05508906 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06784193 | Map |
| MA | Clinical Trial Site | Burlington01805 | NCT07085767 | Map |
| MI | Henry Ford Health | Detroit48126 | NCT05508906 | Map |
| MI | START - Midwest | Grand Rapids49546 | NCT06784193 | Map |
| MN | Clinical Trial Site | Minneapolis55404 | NCT07085767 | Map |
| MN | Regents of the University of Minnesota | Minneapolis55455 | NCT05508906 | Map |
| MO | Clinical Trial Site | Kansas City64132 | NCT07085767 | Map |
| MO | Washington University, School of Medicine | St Louis63110 | NCT05508906 | Map |
| NM | Clinical Trial Site | Santa Fe87505 | NCT07085767 | Map |
| NY | Ichan School of Medicine at Mount Sinai | New York10029 | NCT05508906 | Map |
| NC | Atrium Health Levine Cancer Institute | Charlotte28204 | NCT05508906 | Map |
| NC | Clinical Trial Site | Charlotte28204 | NCT07085767 | Map |
| OH | Clinical Trial Site | Cincinnati45245 | NCT07085767 | Map |
| OH | Clinical Trial Site | Columbus43219 | NCT07085767 | Map |
| PA | Clinical Trial Site | Sayre18840 | NCT07085767 | Map |
| TN | Clinical Trial Site | Bartlett38133 | NCT07085767 | Map |
| TN | Clinical Trial Site | Mount Juliet37122 | NCT07085767 | Map |
| TN | Clinical Trial Site | Nashville37232 | NCT07085767 | Map |
| TN | Henry-Joyce Cancer Clinic, The Vanderbilt Clinic | Nashville37232 | NCT05508906 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06784193 | Map |
| TN | Clinical Trial Site | Tennessee City37203 | NCT07085767 | Map |
| TX | Clinical Trial Site | Denton76201 | NCT07085767 | Map |
| TX | Clinical Trial Site | El Paso79902 | NCT07085767 | Map |
| TX | Clinical Trial Site | Houston77024 | NCT07085767 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT05508906 | Map |
| TX | START - San Antonio | San Antonio78229 | NCT06784193 | Map |
| UT | START - Mountain Region | West Valley City84119 | NCT06784193 | Map |
| VA | Clinical Trial Site | Fort Belvoir22060 | NCT07085767 | Map |
| VA | Clinical Trial Site | Midlothian23114 | NCT07085767 | Map |
| VA | Clinical Trial Site | Norfolk23502 | NCT07085767 | Map |
| WA | Clinical Trial Site | Olympia98502 | NCT07085767 | Map |
| WA | Northwest Medical Specialties | Tacoma98405 | NCT05508906 | Map |
Palazestrant clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P1 | 2 | 1 | 3 |
| P3 | 1 | 1 | 2 |
Recruiting Palazestrant clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07085767 | OPERA-02Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | P3 | Breast Cancer | 1,000 | Nov 2025 |
| NCT05508906 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | P1 | Metastatic Breast Cancer | 190 | Aug 2022 |
| NCT06784193 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | P1 | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | 180 | Dec 2024 |
Palazestrant clinical trials by indication
Breast Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07085767 | OPERA-02 | P3 | recruiting | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer |
| NCT06016738 | OPERA-01 | P3 | active not recruiting | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer |
| NCT05266105 | — | P1 | active not recruiting | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients |
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06784193 | — | P1 | recruiting | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors |
Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05508906 | — | P1 | recruiting | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer |
Palazestrant pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| OPERA-02 | NCT07085767 | P3 | recruiting | Breast Cancer | 1,000 | — |
| OPERA-01 | NCT06016738 | P3 | active not recruiting | Breast Cancer | 510 | PMID 41461598 |
All Palazestrant trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07085767 | OPERA-02 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | P3 | recruiting | 1,000 | Olema Pharmaceuticals, Inc. | Nov 2025 |
| NCT06016738 | OPERA-01 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | P3 | active not recruiting | 510 | Olema Pharmaceuticals, Inc. | Nov 2023 |
| NCT05508906 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | P1 | recruiting | 190 | Olema Pharmaceuticals, Inc. | Aug 2022 | |
| NCT06784193 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | P1 | recruiting | 180 | Olema Pharmaceuticals, Inc. | Dec 2024 | |
| NCT05266105 | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients | P1 | active not recruiting | 60 | Olema Pharmaceuticals, Inc. | Dec 2021 |
Palazestrant clinical trials: frequently asked questions
- How many Palazestrant clinical trials are there?
- 5 Palazestrant clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.
- Are Palazestrant clinical trials recruiting in 2026?
- Yes — 3 Palazestrant trials are actively recruiting in 2026, with 54 U.S. sites across 26 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Palazestrant being studied for?
- Palazestrant is being studied for Metastatic Breast Cancer, Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma, Locally Advanced Breast Cancer and 8 more. The trials are grouped by indication on this page.
- What phase is Palazestrant in?
- Palazestrant clinical trials span 2 Phase 3, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Palazestrant clinical trials?
- The lead sponsor across the most Palazestrant trials is Olema Pharmaceuticals, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Palazestrantas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: